stoxline Quote Chart Rank Option Currency Glossary
Phio Pharmaceuticals Corp. (PHIO)
0.7521  0.003 (0.43%)    05-30 16:00
Open: 0.75
High: 0.78
Volume: 11,870
Pre. Close: 0.7489
Low: 0.73
Market Cap: 3(M)
Technical analysis
2024-05-30 4:43:44 PM
Short term     
Mid term     
Targets 6-month :  0.97 1-year :  1.1
Resists First :  0.83 Second :  0.94
Pivot price 0.75
Supports First :  0.65 Second :  0.54
MAs MA(5) :  0.76 MA(20) :  0.77
MA(100) :  0.74 MA(250) :  1.42
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  48.7 D(3) :  44.6
RSI RSI(14): 49.3
52-week High :  3.45 Low :  0.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PHIO ] has closed above bottom band by 45.9%. Bollinger Bands are 54% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.78 - 0.79 0.79 - 0.79
Low: 0.72 - 0.73 0.73 - 0.73
Close: 0.74 - 0.75 0.75 - 0.76
Company Description

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Headline News

Tue, 28 May 2024
Phio Pharmaceuticals advances to next dose in cancer trial By -

Tue, 28 May 2024
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b ... - Yahoo Finance

Sat, 25 May 2024
We're Keeping An Eye On Phio Pharmaceuticals' (NASDAQ:PHIO) Cash Burn Rate - Yahoo Lifestyle UK

Fri, 17 May 2024
Phio Pharmaceuticals secures investment from TRITON Funds By -

Thu, 16 May 2024
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) - GlobeNewswire

Thu, 16 May 2024
Phio Pharmaceuticals Corp. Forecasted to Post Q2 2024 Earnings of ($0.51) Per Share (NASDAQ:PHIO) - Defense World

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 5 (M)
Shares Float 5 (M)
Held by Insiders 0.5 (%)
Held by Institutions 11 (%)
Shares Short 185 (K)
Shares Short P.Month 21 (K)
Stock Financials
EPS -5.2
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.05
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -59.9 %
Return on Equity (ttm) -116.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.31
Qtrly Earnings Growth 0 %
Operating Cash Flow -11 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -0.15
PEG Ratio 0
Price to Book value 0.36
Price to Sales 0
Price to Cash Flow -0.33
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android